INAB

IN8BIO, INC. (INAB) - 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: IN8BIO, INC.
Reporting Period: Fiscal year ended December 31, 2024.
Business Model: Clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases via its proprietary DeltEx platform.
Key Status: The company has no approved products and has not generated any product revenue. It is focused on advancing clinical trials for INB-100 (hematologic malignancies) and INB-200 (glioblastoma), while suspending enrollment in the INB-400 Phase 2 trial due to cash preservation measures.

Key Financial Metrics

Liquidity: As of December 31, 2024, the company held $11.1 million in cash. Management states that existing cash, combined with subsequent proceeds from an ATM program ($3.7 million in Feb 2025) and warrant exercises ($0.4 million), is not anticipated to fund operations for at least 12 months from the filing date.

Material Changes vs. Prior Period

• Workforce Reduction: In September 2024, the company reduced its workforce by approximately 49% and implemented an 11% reduction in executive cash compensation to preserve capital.
• Pipeline Prioritization: Enrollment in the INB-400 Phase 2 clinical trial for newly diagnosed glioblastoma was suspended in September 2024. The company is now focusing resources on INB-100 and seeking partnerships for INB-400.
• Severance Charges: The company incurred $1.1 million in one-time severance and related charges in 2024, compared to none in 2023.
• Financing Activity: In October 2024, the company completed a private placement raising $11.2 million in net proceeds. During 2024, it also raised $3.8 million via its ATM program.
• Operating Expenses: Total operating expenses remained relatively flat year-over-year ($30.7M vs $30.3M), driven by increased direct clinical costs for INB-100 and INB-400, partially offset by reduced personnel costs and G&A expenses.

Guidance, Outlook, and Risks

Going Concern: The company's independent auditors have issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. The company requires substantial additional funding to finance operations through regulatory approval.

Outlook:

• INB-100: Enrollment in the expansion cohort is ongoing, expected to complete in 2025. Long-term follow-up results anticipated in late 2025 and 2026.
• INB-200: Enrollment completed; long-term follow-up data expected in 2025.
• INB-400: Enrollment suspended; company seeking strategic partners.
• INB-600: New TCE platform; preliminary preclinical data expected in spring 2025.

Key Risks:

• Inability to raise additional capital on acceptable terms or at all.
• Failure of clinical trials to demonstrate safety and efficacy.
• Delisting from Nasdaq due to failure to meet minimum bid price requirements (currently in a compliance period until August 2025).
• Dependence on third-party manufacturers and licensors (Emory University, UABRF).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $11.1M cash balance plus subsequent financing against the projected burn rate, given the "substantial doubt" going concern warning.
• Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the August 4, 2025 compliance deadline to avoid delisting.
• INB-100 Data: Confirm the timeline for the release of long-term follow-up data from the INB-100 expansion cohort, which is critical for de-risking the registrational pathway.
• Partnership Progress: Track any announcements regarding strategic partnerships or licensing deals for the suspended INB-400 program or other assets.
• Warrant Exercises: Assess the likelihood of exercising outstanding Series A, B, and C warrants to generate additional capital, noting the varying exercise prices and expiration dates.